Key Highlights

  • Daiichi Sankyo Co. (TYO: 4568) and AstraZeneca plc (LSE: AZN) secured dual FDA approvals for Enhertu, expanding its use into early HER2-positive breast cancer cases.
  • The drug’s annual sales are projected to reach $5bn, cementing its status as a blockbuster antibody-drug conjugate.
  • Regulators cleared Enhertu for both neoadjuvant and adjuvant settings, offering a new therapeutic pillar for oncologists.
  • AstraZeneca paid $1.35bn upfront in 2019 to co-market the therapy, a bet now vindicated by its rapid Revenue trajectory.
  • Oncology watchers see the approval as a watershed moment, potentially reshaping treatment paradigms in the $25bn HER2-targeted market.

A historic green light for Enhertu

The U.S. Food and Drug Administration’s decision on May 5th—announced jointly by Daiichi Sankyo Co. (TYO: 4568) and AstraZeneca plc (LSE: AZN)—marks the first time an antibody-drug conjugate has been approved for early-stage HER2-positive breast cancer in both the neoadjuvant (pre-surgery) and adjuvant (post-surgery) settings. The dual approvals—granted under the FDA’s Real-Time Oncology Review programme—cover patients with residual invasive disease after neoadjuvant therapy or those with early-stage tumours at high recurrence risk. Clinical data from the DESTINY-Breast05 trial demonstrated a 62% reduction in the risk of invasive disease recurrence or death versus standard chemotherapy, a Margin that prompted regulators to fast-track the decision. Oncologists now have a targeted alternative to traditional cytotoxic regimens, which often carry harsh side-effects.

Financial gravity of the approval

Enhertu’s revenue trajectory underscores its commercial heft. Internal forecasts cited by FiercePharma suggest the drug will generate $5bn in annual sales by 2026—a figure that would place it among the top five oncology therapies globally. The therapy’s growth has outpaced expectations since its initial 2022 approval for metastatic HER2-positive breast cancer, with oncologists increasingly adopting it as a frontline option. AstraZeneca’s $1.35bn upfront payment to Daiichi in 2019—part of a $6.9bn deal structure—has already begun to pay dividends; the British-Swedish giant reported first-quarter oncology revenue of $1.8bn in April, with Enhertu contributing a “meaningful share.” Analysts at SVB Securities estimate the drug could account for 15% of AstraZeneca’s total revenue by 2028, rivalling blockbusters like Tagrisso (AZN).

Market dynamics and competitive pressures

The approval intensifies competition in the HER2-targeted therapy space, a market dominated by Roche’s (OTCQX: RHHBY) Herceptin (trastuzumab) and Perjeta (pertuzumab), which collectively generated $9.2bn in 2023. Whilst Herceptin’s Patent expiry in 2026 threatens biosimilar erosion, Enhertu’s novel mechanism—leveraging Daiichi’s DXd payload—offers a differentiated approach. Yet the drug’s premium pricing—reportedly $9,600 per month—raises reimbursement hurdles, particularly in price-sensitive markets like Europe. Meanwhile, Merck & Co. (NYSE: MRK) and Seagen’s (Nasdaq: SGEN) rival therapy Tukysa (tucatinib) has carved out a niche in metastatic settings, whilst Pfizer’s (NYSE: PFE) recently approved breast cancer drug Elrexfio (elranatamab) targets triple-negative disease. The approval also pressures smaller biotechs developing next-generation ADCs, such as Gilead Sciences’ (NASDAQ: GILD) Trodelvy, which is vying for label expansions in earlier lines.

Regulatory and geopolitical implications

The dual approvals reflect a broader trend of expedited oncology reviews, with the FDA approving 12 new cancer drugs in 2023 alone—a record. The Real-Time Oncology Review programme, which cut the Enhertu approval timeline by 30%, is part of the regulator’s push to accelerate access to therapies with significant survival benefits. Geopolitically, the deal highlights Japan’s growing influence in oncology innovation; Daiichi Sankyo, once known for generics, has emerged as a biotech powerhouse through its ADC platform. The collaboration with AstraZeneca—a European giant—also underscores transatlantic R&D synergies, a trend likely to intensify amid U.S.-China tensions. Regulators in Europe and Japan are expected to follow suit, with EU approval anticipated by Q4 2025 and Japanese clearance in 2026.

Broader economic and healthcare implications

Enhertu’s ascent has implications beyond oncology. Its success validates the ADC class, encouraging Investment in next-generation payloads and linkers—a segment attracting $12bn in venture funding since 2020. For payers, the drug’s cost-effectiveness remains contentious; a 2024 analysis by the Institute for Clinical and Economic Review estimated Enhertu’s price would need to drop 30% to meet standard thresholds in the U.S. system. Yet its ability to reduce recurrence rates could offset long-term healthcare costs by lowering hospitalisations and additional treatments. Meanwhile, the approval bolsters AstraZeneca’s oncology pipeline, which now accounts for 40% of its total revenue—a strategic pivot away from its historic reliance on respiratory drugs. For Daiichi, the milestone reinforces its shift from a traditional pharma company to a biotech innovator, with ADC Assets now contributing 25% of its annual R&D budget.